No­vo Nordisk to launch PhI­II obe­si­ty tri­al for oral semaglu­tide; Edi­Gene ex­tends Se­ries B with ad­di­tion­al $62M

On the heels of a high­ly suc­cess­ful tri­al for its block­buster di­a­betes drug semaglu­tide in obe­si­ty, No­vo Nordisk is prep­ping a Phase II­Ia study for an oral for­mu­la­tion.

The com­pa­ny will launch the tri­al in the sec­ond half of 2021, plan­ning to mea­sure a 50 mg semaglu­tide pill com­pared to place­bo, No­vo an­nounced Wednes­day. The study will re­cruit about 1,000 pa­tients and last for 68 weeks.

“With oral semaglu­tide we aim to in­tro­duce a con­ve­nient and ef­fec­tive treat­ment op­tion for peo­ple with obe­si­ty and health­care providers en­abling broad­er use of an­ti-obe­si­ty med­ica­tion,” said R&D chief Mar­tin Holst Lange in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER